遺伝性血管浮腫（HAE）治療薬の世界市場レポート 2024年

遺伝性血管浮腫（HAE）治療薬の市場規模は近年急速に拡大しています。2023年の57億4,000万米ドルから2024年には67億6,000万米ドルへと、CAGR17.6％で拡大します。過去の期間に見られた拡大は、診断や認知度の向上、治療アクセスの拡大、研究開発イニシアティブ、患者擁護や教育への取り組み、遺伝性血管浮腫（HAE）治療薬分野における規制当局の承認などの要因によるものです。

遺伝性血管浮腫（HAE）の有病率の増加が予想されることから、遺伝性血管浮腫（HAE）治療薬市場の今後の成長が期待されます。遺伝性血管浮腫（HAE）は、皮膚や粘膜の再発性の激しい腫脹を特徴とするまれな遺伝性疾患であり、全世界で約50,000人に1人が罹患し、有病率は1,10,000～1,150,000人と推定されています。これらの症状は、米国だけでも年間15,000～30,000件の救急外来を受診しています。遺伝性血管浮腫（HAE）の発生率の増加は、遺伝性血管浮腫（HAE）治療薬市場の成長を促進する重要な要因です。

北米は、2023年の世界遺伝性血管浮腫（HAE）治療薬市場において最大の地域でした。アジア太平洋は予測期間で最も急成長する地域となる見込みです。遺伝性血管浮腫（HAE）治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 市場促進要因・市場抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模と成長実績、2018～2023年
• 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の遺伝性血管浮腫（HAE）治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• C1エステラーゼ阻害剤
• 選択的ブラジキニンB2受容体拮抗薬
• カリクレイン阻害剤
• その他
• 世界の遺伝性血管浮腫（HAE）治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 静脈内
• 皮下
• 経口
• 世界の遺伝性血管浮腫（HAE）治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• その他
• 世界の遺伝性血管浮腫（HAE）治療薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 予防
• 頓服

第7章 地域および国の分析

• 世界の遺伝性血管浮腫（HAE）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の遺伝性血管浮腫（HAE）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝性血管浮腫（HAE）治療薬市場の競合情勢
• 遺伝性血管浮腫（HAE）治療薬市場の企業プロファイル
  • Shire plc
  • Sanofi SA
  • Pharming Healthcare Inc.
  • Attune Pharmaceuticals Inc.
  • Adverum Biotechnologies Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Hereditary Angioedema Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary angioedema therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hereditary angioedema therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: C1 Esterase Inhibitor; Selective Bradykinin B2 Receptor Antagonist; Kallikrein Inhibitor; Other Drug Classes
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 4) By Application: Prophylaxis; On-demand
• Companies Mentioned: Shire plc; Sanofi S.A.; Pharming Healthcare Inc.; Attune Pharmaceuticals Inc.; Adverum Biotechnologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hereditary angioedema (HAE) therapeutics pertain to the treatment of an autosomal dominant condition caused by a deficiency or malfunction of the C1-inhibitor protein. Symptoms of hereditary angioedema include angioedema-related upper airway, cutaneous, and/or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. C1 Esterase Inhibitor is a protein present in the fluid portion of blood that regulates the complement system's protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and others. The application of hereditary angioedema therapeutics includes prophylaxis and on-demand treatment.

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $5.74 billion in 2023 to $6.76 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The expansion observed in the historical period can be attributed to factors such as improved diagnosis and awareness, the expansion of treatment access, research and development initiatives, patient advocacy and education efforts, and regulatory approvals in the field of hereditary angioedema therapeutics.

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, developments in gene therapy, trends in personalized medicine, and collaborative efforts in research and treatment for hereditary angioedema. Key trends expected in the forecast period encompass global access initiatives, health economic outcomes research, strategies for early intervention, and the development of therapeutics specifically designed for pediatric hereditary angioedema.

The anticipated rise in the prevalence of hereditary angioedema is expected to drive the growth of the hereditary angioedema market in the future. Hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent severe swelling of the skin and mucous membranes, affects approximately 1 in every 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. These episodes result in 15,000 to 30,000 emergency room visits annually in the US alone. The increasing incidence of hereditary angioedema is a significant factor propelling the growth of the hereditary angioedema market.

The growth of the hereditary angioedema therapeutics market is expected to receive a boost from increasing healthcare expenditure. The total amount of resources, including financial resources, allocated to healthcare goods and services within a specific period in a given geographical area is referred to as healthcare expenditure. With a projected annual growth of 5.1% between 2021 and 2030, reaching nearly $6.8 trillion, increased healthcare expenditure enables greater investment in research and development activities. This, in turn, supports the understanding of the underlying causes of hereditary angioedema and the development of innovative therapeutic solutions.

A notable trend gaining traction in the hereditary angioedema therapeutics market is the emphasis on product innovation. Leading companies in this market are actively involved in the development of groundbreaking products, including ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to reinforce their market position. In a significant development, Intellia Therapeutics, a clinical-stage biotechnology company based in the US, introduced an Investigational New Drug (IND) named NTLA-2002 in March 2023. This innovative therapy, approved by the United States Food and Drug Administration for hereditary angioedema treatment, allows the company's ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 segment. NTLA-2002, a candidate for in vivo genome editing, aims to permanently lower plasma kallikrein protein activity and prevent hereditary angioedema attacks after a single dose of therapy through the inactivation of the target gene, kallikrein B1 (KLKB1).

Major players in the hereditary angioedema therapeutics market are also investing in the development of bradykinin B2 receptor antagonists as part of their strategy to reach broader customer bases, drive increased sales, and enhance revenue. An example of this approach is evident in the activities of Cycle Pharmaceuticals, a UK-based biotechnology company. In September 2021, Cycle Pharmaceuticals launched SAJAZIR (icatibant) Injection, an approved treatment by the United States Food and Drug Administration for individuals dealing with Hereditary Angioedema (HAE). Positioned as a bradykinin B2 receptor antagonist, SAJAZIR (icatibant) Injection is specifically designed for the treatment of acute hereditary angioedema attacks in adults aged 18 and above. Its distinctive feature lies in the convenience of a prefilled syringe delivering a 30 mg dose of icatibant. Notably, patients have the capability to self-administer SAJAZIR subcutaneously, following appropriate training provided by healthcare professionals or registered nurses from Cycle Vita, upon recognizing symptoms of an HAE attack.

In February 2023, Takeda Pharmaceutical Company acquired Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC. The acquisition, involving an undisclosed amount, enhances Takeda's late-stage pipeline, contributing to portfolio expansion and broadening its impact across multiple indications. Nimbus Lakshmi is a US-based company specializing in Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market report are Shire plc, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. he hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hereditary Angioedema Therapeutics Market Characteristics

3. Hereditary Angioedema Therapeutics Market Trends And Strategies

4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Hereditary Angioedema Therapeutics Market Size and Growth

• 5.1. Global Hereditary Angioedema Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hereditary Angioedema Therapeutics Market Segmentation

• 6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Other Drug Classes
• 6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Prophylaxis
• On-demand

7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

• 7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hereditary Angioedema Therapeutics Market

• 8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hereditary Angioedema Therapeutics Market

• 9.1. China Hereditary Angioedema Therapeutics Market Overview
• 9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hereditary Angioedema Therapeutics Market

• 10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hereditary Angioedema Therapeutics Market

• 11.1. Japan Hereditary Angioedema Therapeutics Market Overview
• 11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hereditary Angioedema Therapeutics Market

• 12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hereditary Angioedema Therapeutics Market

• 13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hereditary Angioedema Therapeutics Market

• 14.1. South Korea Hereditary Angioedema Therapeutics Market Overview
• 14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hereditary Angioedema Therapeutics Market

• 15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview
• 15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hereditary Angioedema Therapeutics Market

• 16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hereditary Angioedema Therapeutics Market

• 17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hereditary Angioedema Therapeutics Market

• 18.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hereditary Angioedema Therapeutics Market

• 19.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hereditary Angioedema Therapeutics Market

• 20.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hereditary Angioedema Therapeutics Market

• 21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview
• 21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hereditary Angioedema Therapeutics Market

• 22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hereditary Angioedema Therapeutics Market

• 23.1. North America Hereditary Angioedema Therapeutics Market Overview
• 23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hereditary Angioedema Therapeutics Market

• 24.1. USA Hereditary Angioedema Therapeutics Market Overview
• 24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hereditary Angioedema Therapeutics Market

• 25.1. Canada Hereditary Angioedema Therapeutics Market Overview
• 25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hereditary Angioedema Therapeutics Market

• 26.1. South America Hereditary Angioedema Therapeutics Market Overview
• 26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hereditary Angioedema Therapeutics Market

• 27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hereditary Angioedema Therapeutics Market

• 28.1. Middle East Hereditary Angioedema Therapeutics Market Overview
• 28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hereditary Angioedema Therapeutics Market

• 29.1. Africa Hereditary Angioedema Therapeutics Market Overview
• 29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape
• 30.2. Hereditary Angioedema Therapeutics Market Company Profiles
  • 30.2.1. Shire plc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Sanofi S.A.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Pharming Healthcare Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Attune Pharmaceuticals Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Adverum Biotechnologies Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking

32. Global Hereditary Angioedema Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

34. Hereditary Angioedema Therapeutics Market Future Outlook and Potential Analysis

• 34.1 Hereditary Angioedema Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Hereditary Angioedema Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Hereditary Angioedema Therapeutics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer